Early Heart Screening Prevents Sudden Cardiac Death

Tumor markers are substances produced by cancer cells or by the body in response to cancer or certain benign conditions. These markers can be found in blood, urine, stool, tumor tissue, or other tissues and bodily fluids. Healthcare providers use tumor marker tests to help detect, diagnose, and manage certain types of cancer. While tumor markers can provide valuable information, they are rarely used alone to diagnose cancer because many noncancerous conditions can also cause elevated levels.

Common tumor markers include CA 125, which is associated with ovarian cancer; CA 19-9, used primarily for pancreatic cancer; CEA (carcinoembryonic antigen), which can indicate colorectal and other cancers; PSA (prostate-specific antigen) for prostate cancer; and AFP (alpha-fetoprotein), which may be elevated in liver cancer. Other markers include CA 15-3 for breast cancer, CA 27-29 also for breast cancer, and HCG (human chorionic gonadotropin) for testicular and ovarian cancers. Each marker has specific uses and limitations in cancer detection and monitoring.

Tumor marker tests serve several important purposes in cancer care. They can help screen for cancer in certain high-risk populations, assist in diagnosing cancer when combined with other tests, determine the extent or stage of cancer, predict how aggressive a cancer might be, plan appropriate treatment strategies, and assess whether treatment is working effectively. Additionally, these tests are valuable for monitoring cancer recurrence after treatment has been completed. The frequency of testing depends on the type of cancer, treatment stage, and individual patient factors.

It is important to understand that elevated tumor marker levels do not always mean cancer is present. Many benign conditions, including infections, inflammation, liver disease, kidney disease, and other noncancerous disorders can cause increased levels. Similarly, not all cancers produce elevated tumor markers, and some people with cancer may have normal marker levels. This is why tumor marker tests are typically used in combination with other diagnostic procedures such as imaging studies, biopsies, and physical examinations rather than as standalone diagnostic tools.

Patients should discuss with their healthcare provider what specific tumor markers are being tested, why they are being measured, and how the results will be interpreted in the context of their overall health status. Understanding the limitations and appropriate uses of tumor marker testing helps patients and providers make informed decisions about cancer screening, diagnosis, treatment monitoring, and follow-up care. Regular monitoring of tumor markers, when appropriate, can be an important part of comprehensive cancer management and surveillance.